Grant Funded Reserach
Founded in 2002, Cellex Incorporated is a biotech company that develops technologies, instruments and assays for testing of human diseases and conditions, particularly for point-of-care (POC) professional healthcare settings. Based in Morrisville, NC, the company maintains both a GMP manufacturing site in Suzhou.
~ 23.5 K
People employed in R&D
$ 17.9 B
Invested in R&D in 2024
1,400 +
Publications by our scientists
Our research in action
Boosting anti-tumor responses by combining foundational cancer treatments with negative immune regulators that play different roles in adjusting the immune response.
Project classification of NIH
Boosting anti-tumor responses by combining foundational cancer treatments with negative immune regulators that play different roles in adjusting the immune response.
Activyl®
(indoxacarb) U.S. Patent No. 8,475,818
BRAVECTO®
(fluralaner) chews Flavored chews for dogs U.S. Patent No. 7,662,972 U.S. Patent No. 11,285,101
BOVILIS Nasalgen 3 PMH
Live cattle vaccineU.S. Patent No. 9,642,905U.S. Patent No. 9,662,382
BOVILIS@ Coronavirus
Live Bovine Coronavirus VaccineU.S. Patent No. 10,434,168 B2
BRAVECTO@
(fluralaner) topical solution dogs and cats U.S. Patent No. 7,662,972 U.S. Patent No. 9,532,978 U.S. Patent No. 9,173,870
BRAVECTO@
(fluralaner) topical solution dogs and cats U.S. Patent No. 7,662,972 U.S. Patent No. 9,532,978 U.S. Patent No. 9,173,870
Read our R&D stories
Exploring the potential use of PET tracers in neurodegenerative disease research
Our teams of researchers and scientists are pushing the boundaries of cancer research to discover more effective anticancer therapies.
Exploring the potential use of PET tracers in neurodegenerative disease research
Our teams of researchers and scientists are pushing the boundaries of cancer research to discover more effective anticancer therapies.
Exploring the potential use of PET tracers in neurodegenerative disease research
Our teams of researchers and scientists are pushing the boundaries of cancer research to discover more effective anticancer therapies.
Exploring the potential use of PET tracers in neurodegenerative disease research
Our teams of researchers and scientists are pushing the boundaries of cancer research to discover more effective anticancer therapies.
